Breakthrough pain: Progress in management

Current Opinion in Oncology

Volumn 22, Issue 4, 2010, Pages 302-306

  Lossignol, Dominique A ^a   Dumitrescu, Cristina ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

breakthrough pain; cancer; fentanyl

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTITUSSIVE AGENT; FENTANYL; FENTANYL CITRATE; HYDROMORPHONE; LOCAL ANESTHETIC AGENT; METHADONE; MORPHINE; OPIATE DERIVATIVE; OXYCODONE;

ANALGESIA; BREAKTHROUGH PAIN SYNDROME; CANCER DIAGNOSIS; CANCER PAIN; CANCER PATIENT; CANCER THERAPY; CLINICAL TRIAL; COUGHING; DIAGNOSTIC ACCURACY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; HEADACHE; HUMAN; MEDICAL LITERATURE; MEDLINE; NAUSEA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANALGESICS, OPIOID; FENTANYL; HUMANS; NEOPLASMS; PAIN; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 77953914835     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833a873a     Document Type: Review

References (19)

1. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence ands characteristics. Pain 1990; 41:273-281.
2. Caraceni A, Martini C, Zecca E, Portenoy RK. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004; 18:177-183.
3. Fortner BV, Demarco G, Irving G, et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage 2003; 25:9-18.
4. Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999; 79:303-312.
5. Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2: Management P&T 2005; 30:354-358.
6. Coluzzi PH, Schwartzberg L, ConroyJr JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulphate immediate release (MSIR). Pain 2001; 91:123-130.
7. Fine PG, Marcus M, Just De Boer A, Van der Oord B. An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain 1991; 45:149-153.
8. Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998; 90:611-616.
9. Lee M, Pharm D, Kern SE, et al. A pharmacokinetic study to compare two simultaneous 400mg doses with single 800mg dose of oral transmucosal fentanyl citrate. J Pain Symptom Manage 2002; 26:743-747.
10. Straisand JB, Varvel JR, Stanski DR, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991; 75:223-229.
11. Tateishi T, Krivoruk Y, Ueng Y-F, et al. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-deal-kylation. Anesth Analg 1996; 82:167-172.
12. Grape S, Schug SA, Lauer S, et al. Formulation of fentanyl for the management of pain. Drugs 2010; 70:57-72.
13. Rauck RL, Tark M, Reyes E, et al. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. Curr Med Res Opin 2009; 25:2877-2885.
14. Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer 2009; 15:3372.
15. RauckR, North J, Gever N, etal. Fentanyl buccal film (FBSF) for breakthrough pain in patient with cancer: a randomised, double-blind, placebo-controlled study. Ann Oncol 2009. [Epub ahead of print]
16. Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomized, crossover trial. Curr Med Res Opin 2009; 25:2805-2815.
17. Fischer A, Watling M, Smith A, et al. Pharmacokinetic comparison of three nasal fentanyl formulation: pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol Ther 2010; 48:138-145.
18. Davies AN, Dickman A, Reid C, et al., Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Breakthrough cancer pain. Br Med J 2008; 337:a2689.
19. European Medicine Agency. Assessment report for Instanyl. London; July 2009.